"Diabetes and Weight-Loss Drug Shortages: Limited Supply Challenges Pharmacies"
TL;DR Summary
Most doses of Eli Lilly's weight loss drug Zepbound and diabetes drug Mounjaro will be in short supply through the second quarter of 2024 due to surging demand, according to the FDA. The shortage affects all doses except the 2.5-milligram versions. The company is working to increase production capacity and expects significant increases in the second half of the year, with new facilities planned for the future. The shortage reflects the high demand for these drugs, which are known as incretin drugs and are used for weight loss and diabetes management.
- Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says CNBC
- Zepbound Shortage: Almost All Doses Are in Short Supply Through Mid-Year Bloomberg
- Pharmacies dealing with shortage of diabetes drugs WHSV
- Weight-loss drug shortage result of 'unprecedented demand' Yahoo Finance
- Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA says Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
83%
544 → 91 words
Want the full story? Read the original article
Read on CNBC